THE LEADING RNAi THERAPEUTICS COMPANY
Alnylam’s pioneering science has yielded the critical breakthroughs and innovations that have made RNA interference (RNAi)-based medicines a reality.
We ushered in the first phase of the RNAi RevolutionTM by developing the first five approved RNAi therapeutics. Now, we’re pioneering what’s next, working to bring RNAi therapeutics to a broad spectrum of difficult-to-treat diseases, both rare and which impact millions of people around the world.
Silencing genes to disrupt disease
RNA interference (RNAi) is a naturally occurring process already at work inside your body which regulates how genes make new proteins. Proteins play a critical role in almost everything your body does, but sometimes, they can cause or contribute to disease. Our medicines leverage the RNAi process to prevent specific proteins from being made, disrupting disease at its source.
We believe that this revolutionary approach can be used to silence virtually any gene in the genome… meaning that the diseases we’re treating today are just the beginning of what’s possible.
OUR PIPELINE
Our robust pipeline of investigational RNAi therapeutics is currently focused on diseases with high unmet medical need, including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases, and neurological diseases. Additionally, we will always follow the science and are continually looking for new disease targets that may benefit from our RNAi technology.
Genetic Medicines
Cardio-Metabolic Diseases
Infectious Diseases
Central Nervous System & Ocular Diseases
PATIENTS COME FIRST
While we’re driven by science, we’re motivated by people because for us, this is personal. Whether we're working to develop the first treatment for a disease or a better one, patients are the center of all we do. They are the reason we come to work every day, and their stories inspire us to continue to innovate by pushing the science of RNAi therapeutics forward.
My body started to warn me that something was wrong. That I had a problem… My father passed away 40 years ago; after I received my diagnosis, we believe what he really had was hATTR amyloidosis like me.
-Chen, living with hATTR amyloidosis
ALNYLAM NEWS
OUR COMMITMENTS
Accepting Challenges to Improve the Health of Humanity
We believe that our actions as a company can be a force for good in the world both inside our labs and beyond. We aspire to make a positive impact in the world beyond the medicines we make through focusing on patients, science, employees, communities, our planet and corporate governance.
We're Driven to Change the World
We are proud of the award-winning, open, dynamic, and diverse culture we have built. Here, our employees feel included, supported, and heard. We are committed to building a work environment with a shared mission and values, where all employees are enabled to achieve their full potential.
This is your moment to join us
We're 2,000+ smart, passionate, "change the world" kind of people who believe deeply in the power and potential of our technology and what we're building as a company. If you are looking for a mission, colleagues that inspire, and a company that recognizes and rewards both group and individual contributions, perhaps this is your moment to join us.
JOIN US ›
